Compare PRK & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | LGND |
|---|---|---|
| Founded | 1908 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 1996 | N/A |
| Metric | PRK | LGND |
|---|---|---|
| Price | $172.04 | $234.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $184.00 | ★ $256.29 |
| AVG Volume (30 Days) | 63.3K | ★ 176.4K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $664,421,000.00 | N/A |
| Revenue This Year | $24.26 | $1.25 |
| Revenue Next Year | $3.63 | $19.41 |
| P/E Ratio | ★ $72.37 | $76.27 |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $149.06 | $103.43 |
| 52 Week High | $179.48 | $247.38 |
| Indicator | PRK | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 60.38 |
| Support Level | $169.82 | $199.97 |
| Resistance Level | $176.73 | $237.54 |
| Average True Range (ATR) | 3.25 | 7.03 |
| MACD | 0.16 | 1.11 |
| Stochastic Oscillator | 91.92 | 86.44 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.